MX2019010982A - Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos. - Google Patents
Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos.Info
- Publication number
- MX2019010982A MX2019010982A MX2019010982A MX2019010982A MX2019010982A MX 2019010982 A MX2019010982 A MX 2019010982A MX 2019010982 A MX2019010982 A MX 2019010982A MX 2019010982 A MX2019010982 A MX 2019010982A MX 2019010982 A MX2019010982 A MX 2019010982A
- Authority
- MX
- Mexico
- Prior art keywords
- designer
- activated
- modified receptor
- modified
- patient
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 4
- 239000000747 designer drug Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000008062 neuronal firing Effects 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/10—Vectors comprising a special origin of replication system multiple origins of replication
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471635P | 2017-03-15 | 2017-03-15 | |
| US201762608207P | 2017-12-20 | 2017-12-20 | |
| US201862635871P | 2018-02-27 | 2018-02-27 | |
| PCT/US2018/022573 WO2018170223A1 (en) | 2017-03-15 | 2018-03-15 | Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010982A true MX2019010982A (es) | 2020-02-10 |
Family
ID=63523332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010982A MX2019010982A (es) | 2017-03-15 | 2018-03-15 | Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190060400A1 (https=) |
| EP (1) | EP3595669A4 (https=) |
| JP (1) | JP2020511473A (https=) |
| KR (1) | KR20190124309A (https=) |
| CN (1) | CN110621318A (https=) |
| AU (1) | AU2018234644A1 (https=) |
| BR (1) | BR112019019078A2 (https=) |
| CA (1) | CA3056410A1 (https=) |
| IL (1) | IL269310A (https=) |
| MX (1) | MX2019010982A (https=) |
| WO (1) | WO2018170223A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002148A (es) * | 2017-08-25 | 2020-07-20 | Ovid Therapeutics Inc | Vectores adenoasociados recombinantes. |
| CA3084985A1 (en) | 2017-12-06 | 2019-06-13 | Ovid Therapeutics Inc. | Use of mir101 or mir128 in the treatment of seizure disorders |
| WO2019113538A2 (en) * | 2017-12-07 | 2019-06-13 | California Institute Of Technology | Methods and systems for noninvasive control of brain cells and related vectors and compositions |
| CN111867595A (zh) * | 2017-12-20 | 2020-10-30 | 奥维德医疗公司 | hM4Di在治疗癫痫发作紊乱中的用途 |
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| MX2022009982A (es) * | 2020-02-14 | 2022-09-12 | Ultragenyx Pharmaceutical Inc | Terapia genica para el tratamiento de transtorno por deficiencia de cdkl5. |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| KR102878106B1 (ko) * | 2021-12-24 | 2025-10-28 | 서울대학교산학협력단 | 신경수초 가소성 증진 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003221733A1 (en) * | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
| GB201404470D0 (en) * | 2014-03-13 | 2014-04-30 | Ucl Business Plc | Therapeutic methods and materials |
-
2018
- 2018-03-15 CA CA3056410A patent/CA3056410A1/en active Pending
- 2018-03-15 WO PCT/US2018/022573 patent/WO2018170223A1/en not_active Ceased
- 2018-03-15 MX MX2019010982A patent/MX2019010982A/es unknown
- 2018-03-15 CN CN201880030980.6A patent/CN110621318A/zh active Pending
- 2018-03-15 EP EP18768245.5A patent/EP3595669A4/en not_active Withdrawn
- 2018-03-15 US US15/921,906 patent/US20190060400A1/en not_active Abandoned
- 2018-03-15 BR BR112019019078A patent/BR112019019078A2/pt not_active IP Right Cessation
- 2018-03-15 AU AU2018234644A patent/AU2018234644A1/en not_active Abandoned
- 2018-03-15 KR KR1020197030149A patent/KR20190124309A/ko not_active Withdrawn
- 2018-03-15 JP JP2019551284A patent/JP2020511473A/ja active Pending
-
2019
- 2019-09-12 IL IL26931019A patent/IL269310A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3595669A4 (en) | 2021-03-03 |
| KR20190124309A (ko) | 2019-11-04 |
| WO2018170223A1 (en) | 2018-09-20 |
| US20190060400A1 (en) | 2019-02-28 |
| BR112019019078A2 (pt) | 2020-04-22 |
| EP3595669A1 (en) | 2020-01-22 |
| IL269310A (en) | 2019-11-28 |
| AU2018234644A1 (en) | 2019-10-03 |
| CA3056410A1 (en) | 2018-09-20 |
| JP2020511473A (ja) | 2020-04-16 |
| CN110621318A (zh) | 2019-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010982A (es) | Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos. | |
| ZA201903091B (en) | Methods of treating inflammatory conditions | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MX378635B (es) | Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia. | |
| MX2022007989A (es) | Composiciones y metodos para tratar pterigion. | |
| NZ739392A (en) | Methods for treating hepcidin-mediated disorders | |
| MX2016010854A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r. | |
| PH12017501857B1 (en) | Pd-l1 antagonist combination treatments | |
| NZ751746A (en) | Combination therapy with controlled-release cnp agonists | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| BR112017008093A2 (pt) | processos para tratamento de doenças oculares | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MX385287B (es) | Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| MX386613B (es) | El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto. | |
| PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
| MX2019014483A (es) | Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis. | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| MX2017007054A (es) | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. |